MacTel Type 1

A patient presented with chronic cystoid macular edema (CME) in the left eye. His BCVA OS was 20/60. Despite prior long-term interventions with intravitreal steroids and anti-VEGF agents (ranibizumab and aflibercept), the macular edema persisted, prompting the exploration of alternative therapeutic avenues. The case highlights the effectiveness of Brolucizumab as a treatment option in managing MacTel 1-associated macular edema when traditional anti-VEGF therapies prove insufficient. Because of its side effect profile, we have attempted to switch the patient to newer and safer therapies such as faricimab, but the edema recurred. After a careful understanding of the risks and benefits, the patient has continued treatment with brolucizumab without complications and maintains 20/20 vision. The case underscores the importance of individualized approaches in addressing complex retinal disorders, shedding light on the evolving landscape of treatment strategies for MacTel 1 and associated macular complications.

Presentation Date: 11/30/2023

Issue Date: 12/15/2023